Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 5 (4), 343-54

Secondary Progressive Multiple Sclerosis: Current Knowledge and Future Challenges


Secondary Progressive Multiple Sclerosis: Current Knowledge and Future Challenges

Marco Rovaris et al. Lancet Neurol.


The secondary progressive phase of multiple sclerosis (MS), which is characterised by a steady accrual of fixed disability after an initial relapsing remitting course, is not clearly understood. Although there is no consensus on the mechanisms underlying such a transition to the progressive phase, epidemiological and neuroimaging studies indicate that it is probably driven by the high prevalence of neurodegenerative compared with inflammatory pathological changes. This notion is lent support by the limited efficacy of available immunomodulating and immunosuppressive treatment strategies, which seems to be further decreased in the late stages of secondary progressive MS. No established clinical or paraclinical predictors of the transition from relapsing remitting to secondary progressive MS have been described. However, the use of quantitative MRI-derived measures is warranted to monitor natural history studies and therapeutic trials of secondary progressive MS with increased reliability. In view of the small effects of immunomodulating and immunosuppressive treatments in preventing the transition to secondary progression, the development of treatments promoting neuroaxonal repair remains an important goal in this disease.

Similar articles

  • [Immunomodulatory Therapy in Multiple Sclerosis]
    T Csépány et al. Ideggyogy Sz 57 (11-12), 401-16. PMID 15662768. - Review
    During the past decade, several disease-modifying agents have been established and have become available for the treatment of multiple sclerosis. The disease-modifying ag …
  • Natural History of Multiple Sclerosis: A Unifying Concept
    C Confavreux et al. Brain 129 (Pt 3), 606-16. PMID 16415308.
    Multiple sclerosis can follow very different patterns of evolution and variable rates of disability accumulation. This raises the issue whether it represents one or sever …
  • Management of Multiple Sclerosis: Current Trials and Future Options
    JH Noseworthy. Curr Opin Neurol 16 (3), 289-97. PMID 12858064. - Review
    The MS research community needs to determine how best to address two key unanswered questions. Is late clinical deterioration often or invariably tied to the initial infl …
  • Current Disease-Modifying Therapies in Multiple Sclerosis
    BC Kieseier et al. Semin Neurol 23 (2), 133-46. PMID 12894379. - Review
    In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been established. Interfer …
  • Immunotherapy of Multiple Sclerosis--Current Practice and Future Directions
    MJ Tullman et al. J Rehabil Res Dev 39 (2), 273-85. PMID 12051470. - Review
    Over the past decade, multiple sclerosis (MS) has become a treatable neurological disease. This paper reviews the therapies that have been studied to treat MS and discuss …
See all similar articles

Cited by 60 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms


LinkOut - more resources